We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · July 06, 2021

Sintilimab Plus a Bevacizumab Biosimilar vs Sorafenib in Unresectable Hepatocellular Carcinoma

The Lancet Oncology


Additional Info

The Lancet Oncology
Sintilimab Plus a Bevacizumab Biosimilar (IBI305) Versus Sorafenib in Unresectable Hepatocellular Carcinoma (ORIENT-32): A Randomised, Open-Label, Phase 2-3 Study
Lancet Oncol 2021 Jun 15;[EPub Ahead of Print], Z Ren, J Xu, Y Bai, A Xu, S Cang, C Du, Q Li, Y Lu, Y Chen, Y Guo, Z Chen, B Liu, W Jia, J Wu, J Wang, G Shao, B Zhang, Y Shan, Z Meng, J Wu, S Gu, W Yang, C Liu, X Shi, Z Gao, T Yin, J Cui, M Huang, B Xing, Y Mao, G Teng, Y Qin, J Wang, F Xia, G Yin, Y Yang, M Chen, Y Wang, H Zhou, J Fan

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.